AbbVie Inc. (NYSE:ABBV) on Wednesday reported first-quarter 2026 sales of $15.00 billion, beating the consensus of $14.72 billion.
AbbVie Q1 Revenue Beats Driven By Immunology Growth
Sales increased 12.4% on a reported basis or 10.3% on an operational basis. The company reported adjusted earnings of $2.65 per share, up 7.7%, beating the consensus of $2.59.
Global net revenues from the immunology portfolio were $7.29 billion, up 16.4% (+14.3% on an operational basis), including Skyrizi sales, which increased 30.9% to $4.48 billion; Rinvoq sales reached $2.12 billion, an increase of 23.3%; and Humira sales fell 38.6% to $688 million.
data-variant=”banner”
data-news-mode=”manual”
>
Read Also:
AbbVie Faces FDA Rejection On Manufacturing Issues For Wrinkle Drug